This public-private partnership seeks to develop new ways of identifying and validating promising biological targets for diagnostics and drug development.
PEPR Overview The Validation of Pediatric Patient Reported Outcomes in Chronic Diseases (PEPR) Consortium (U19) will capitalize on recent advances in the science of Patient Reported Outcomes (PROs) to assess the health of children with a variety of chronic diseases and conditions in clinical research and care settings. Examples of
The human back is a complex structure with bones, nerves, tendons, discs, and more — all places where something can go wrong and cause pain, which, for many people, becomes a long-term or chronic problem. Life stresses and other medical and mental health conditions aggravate the problem. With so many pieces, it’s hard to get a holistic view of the puzzle or pinpoint the cause of the pain. “People tend to focus on one aspect or another,” said Jeffrey Lotz, Ph.D., a medical engineer who studies back pain at the University of California, San Francisco. “Some people think it’s largely
NIH study shows genomic variation causing common autoinflammatory disease may increase resilience to bubonic plague
this page refers users to original article.
A research team led by Dr. Makarand Risbud of Thomas Jefferson University tested whether treatment with the drugs dasatinib and quercetin would prevent disc degeneration in mice. Both drugs are senolytics, which selectively remove aged cells known as senescent cells.
A researcher from Stanford University asked IRP investigator Michael Ombrello, M.D., to help her team follow a new lead in the mystery of why some patients with a rare inflammatory condition called Still’s disease were coming down with a life-threatening lung ailment.
Human skin is home to diverse ecosystems including bacteria, viruses, and fungi. These microbial communities comprise hundreds of species and are collectively known as the skin microbiome.
Researchers published a proof-of-principle paper in the journal Science Immunology demonstrating just how precision medicine for inflammatory skin rashes might work.
A treatment for severe skin inflammation that works well in lean mice made the condition worse in obese mice because of immune-cell changes associated with obesity.
The FDA approved Olumiant (baricitinib) oral tablets to treat adult patients with severe alopecia areata. The action marks the first FDA approval of a systemic treatment (i.e. treats the entire body rather than a specific location) for alopecia areata.